Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Divi's-Laboratories-Limited"

4 News Found

Divi's Laboratories to expand capacity at an outlay of approx. Rs. 700 Cr
News | April 26, 2024

Divi's Laboratories to expand capacity at an outlay of approx. Rs. 700 Cr

The proposed facility is expected to be operational around January, 2027

Divis Laboratories posts Q2 FY24 consolidated PAT at Rs. 348 Cr
News | November 07, 2023

Divis Laboratories posts Q2 FY24 consolidated PAT at Rs. 348 Cr

Divi's Laboratories Limited has reported total income of Rs. 1995 crores during the period ended September 30, 2023

USFDA delegation visits Divi's Laboratories’ Unit I at Choutuppal, Telangana
Drug Approval | September 29, 2023

USFDA delegation visits Divi's Laboratories’ Unit I at Choutuppal, Telangana

The delegation's visit covered a wide range of topics

Divis Labs PAT at Rs 606.46 cr. in Q2FY22
News | November 08, 2021

Divis Labs PAT at Rs 606.46 cr. in Q2FY22

Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.

Latest Stories

Glenmark receives ANDA approval for Brimonidine Tartrate and Timolol Maleate ophthalmic solution

Mankind Pharma launches 'Limit White India' campaign to raise hypertension awareness

Arvinas and Pfizer announce updated clinical data from Phase 1b Trial of Vepdegestrant in combination with Palbociclib

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
Vinod Paremal President & MD, Evonik, India Region

Packaging